Trials / Completed
CompletedNCT03002376
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Indicators of Clinical Response in Immunomodulatory Treatment-naïve Unresectable Stage III/IV Melanoma Patients Receiving REGN2810 (Anti-PD-1)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to compare the relationship of patient response to treatment to changes in tumor environment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN2810 | REGN2810 treatment |
Timeline
- Start date
- 2017-04-10
- Primary completion
- 2019-03-05
- Completion
- 2020-03-19
- First posted
- 2016-12-23
- Last updated
- 2020-04-20
Locations
8 sites across 4 countries: Netherlands, Serbia, South Korea, United Kingdom
Source: ClinicalTrials.gov record NCT03002376. Inclusion in this directory is not an endorsement.